Stefan Fröhling 9 months ago
PAMSARC: Newly opened, academic phase 2 trial, enabled by DKFZ NCT/DKTK MASTER and HEROES-AYA, evaluating pasireotide as maintenance therapy in patients with synovial sarcoma and desmoplastic small round cell tumor and aberrant expression of somatostatin receptor family members (NCT06456359)
add a skeleton here at some point